Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Duodenal Diseases

ClinicalTrials.gov lists 434 trials for Duodenal Diseases or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 34.

MeSH D004378 Digestive System Diseases C06
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 28 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 25 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 71 Phase 4 Phase 4 69 Not applicable Not applicable 113 Observational Observational 115 Phase 1 Phase 1 28 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 25 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 71 Phase 4 Phase 4 69 Not applicable Not applicable 113 Observational Observational 115

Trials per phase (log scale)

4 of the 434 trials are tagged with Duodenal Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Duodenal Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Duodenal Diseases trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 29

1991: 1 trials (Observational 1) 1996: 4 trials (Phase 4 1, Phase 1 3) 1997: 2 trials (Observational 1, Phase 1 1) 1999: 2 trials (Observational 1, Not applicable 1) 2000: 4 trials (Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 1) 2001: 9 trials (Not applicable 1, Phase 3 6, Phase 2 1, Phase 1 1) 2002: 3 trials (Observational 3) 2003: 6 trials (Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 1) 2004: 14 trials (Observational 4, Not applicable 2, Phase 4 5, Phase 3 1, Phase 2 2) 2005: 13 trials (Not applicable 2, Phase 4 5, Phase 3 5, Phase 2 1) 2006: 12 trials (Not applicable 2, Phase 4 2, Phase 3 5, Phase 2 1, Phase 1 2) 2007: 25 trials (Observational 4, Not applicable 2, Phase 4 5, Phase 3 12, Phase 2 2) 2008: 13 trials (Observational 4, Not applicable 2, Phase 4 2, Phase 3 2, Phase 2/3 2, Phase 2 1) 2009: 17 trials (Observational 5, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 1 3) 2010: 19 trials (Observational 6, Not applicable 4, Phase 4 3, Phase 3 3, Phase 2/3 1, Phase 1 2) 2011: 22 trials (Observational 9, Not applicable 2, Phase 4 3, Phase 3 5, Phase 2/3 2, Phase 2 1) 2012: 23 trials (Observational 6, Not applicable 4, Phase 4 3, Phase 3 7, Phase 2 2, Phase 1 1) 2013: 16 trials (Observational 7, Not applicable 5, Phase 4 2, Phase 2/3 1, Phase 1 1) 2014: 15 trials (Observational 4, Not applicable 2, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1 2) 2015: 13 trials (Observational 6, Not applicable 3, Phase 4 2, Phase 2 1, Phase 1 1) 2016: 19 trials (Observational 5, Not applicable 5, Phase 4 4, Phase 3 2, Phase 2/3 2, Phase 1 1) 2017: 19 trials (Observational 8, Not applicable 3, Phase 4 3, Phase 3 2, Phase 2 1, Phase 1/2 1, Phase 1 1) 2018: 8 trials (Observational 3, Not applicable 2, Phase 4 2, Phase 3 1) 2019: 10 trials (Observational 3, Not applicable 6, Phase 4 1) 2020: 18 trials (Observational 7, Not applicable 7, Phase 4 2, Phase 2 1, Phase 1/2 1) 2021: 14 trials (Observational 4, Not applicable 4, Phase 4 2, Phase 3 4) 2022: 19 trials (Observational 4, Not applicable 9, Phase 4 2, Phase 3 1, Phase 2 2, Phase 1 1) 2023: 29 trials (Observational 3, Not applicable 14, Phase 4 5, Phase 3 1, Phase 2 2, Phase 1 4) 2024: 19 trials (Not applicable 14, Phase 4 2, Phase 3 3) 2025: 20 trials (Observational 5, Not applicable 8, Phase 4 4, Phase 3 1, Phase 2 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 17
2025 20
2024 19
2023 29
2022 19
2021 14
2020 18
2019 10
2018 8
2017 19

Showing 10 of 31 earlier years.

Start your 14-day trial Email me all 31 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 19 trials starting in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 27 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 267 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Duodenal Diseases trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 28
Phase 1/2 2
Phase 2 25
Phase 2/3 11
Phase 3 71
Phase 4 69
Not applicable 113
Observational 115

How many Duodenal Diseases trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 20
Recruiting 41
Enrolling by invitation 3
Active, not recruiting 4
Completed 271

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Duodenal Diseases trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 34
Takeda 30
POZEN 8
Eisai Co., Ltd. 7
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 7

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Duodenal Diseases? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Omeprazole 20 mg 17
E3810 13
Amoxicillin 13
Magnesium Pantoprazole 11
Natrol 11

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Nexium Pill 35
lansoprazole OD 28
Vonoparazan 20
Clarithromycin XL 10
EC Aspirin 7

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Duodenal Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Angina pectoris 36 9
Pneumonia 33 16
Gastric cancer 21 8
Cerebral infarction 17 8
Death 14 5

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Duodenal Diseases? (59)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Gastric Alimetry Expands Patient Phenotyping in Gastroduodenal Disorders Compared with Gastric Emptying Scintigraphy. The American journal of gastroenterology 2024 Yes
Impact of periampullary diverticulum on biliary cannulation and ERCP outcomes: a single-center experience. Surgical endoscopy 2021 Yes
Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia. Gastroenterology 2021 Yes
The role of endoscopy in the management of suspected small-bowel bleeding. Gastrointestinal endoscopy 2017 Yes
Gastroduodenal Disorders. Gastroenterology 2016 Yes

Showing 5 of 59 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages